Navigation Links
Women Using Compounded 'Bioidentical' Hormones Miss the Full Story About These Drugs
Date:12/31/2008

MONTVALE, N.J., Dec. 31 /PRNewswire/ -- Women in, or past, menopause who use specially compounded "bioidentical" hormones to treat menopause-related symptoms, such as hot flushes, often don't get adequate information from compounding pharmacists about the drugs' risks and realistic potential for benefit. That's one of the concerns about these medications addressed by menopause expert JoAnn V. Pinkerton, MD, in "'Bioidentical' hormones: What you (and your patient) need to know," in the January issue of OBG Management.

So-called bioidentical hormones are chemically similar to hormones released by the body, including those produced in the ovaries -- estrone, estradiol, estriol, progesterone, testosterone, and dehydroepiandrosterone, to name some.

"The FDA has approved many prescription products that contain 'bioidentical' hormones," says Pinkerton, "but 'bioidentical' is often used to refer to custom-compounded hormones. The major difference between FDA-approved prescription bioidentical hormone products and custom-compounded products is that only the former are regulated by the FDA and tested for purity, potency, efficacy, and safety."

"That means it's up to physicians who prescribe compounded hormones to educate their patients -- about potential risks and benefits, absence of FDA oversight, purity and potency concerns, and lack of peer-reviewed data on efficacy and safety," Pinkerton says.

"Practitioners need to recognize that women who ask for these hormones may be vulnerable -- because of anxiety and depression that often accompany menopausal symptoms -- to unsubstantiated claims or recommendations of self-proclaimed experts."

"Compounded hormones aren't safer, or more effective, than traditional FDA-approved hormone therapies," Pinkerton emphasizes. "No data support individualized, personalized therapy based on testing hormone levels in saliva. And compounded bioidentical hormones don't prevent cancer; they probably have the same potential to cause cancer, and present the same other health risks, as FDA-approved hormones."

Bioidentical hormones are one of the biggest products of the multibillion-dollar US pharmaceutical compounding industry, observes Bruce Patsner, MD, JD, who contributed to the OBG Management article. Patsner, an expert on pharmacy compounding of prescription hormone therapy, served as senior medical officer at the FDA and is now Research Professor of Law at the University of Houston Law Center.

JoAnn V. Pinkerton, MD, is Professor and Vice Chair of Obstetrics and Gynecology at the University of Virginia Health System in Charlottesville, where she directs The Women's Place Midlife Health Center. She is a member of the Board of Editors of OBG Management, a review publication for ObGyns (www.obgmanagement.com).


'/>"/>
SOURCE Dowden Health Media
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Work-Family Conflict Dogs Air Force Women After Deployment
3. Work-Family Conflict Dogs Air Force Women After Deployment
4. Antioxidant Supplements May Raise Womens Skin Cancer Risk
5. Early Weight Loss in Women Linked to Dementia
6. For Health Info, Women Often Turn to the Web
7. Smoking increases risks for head and neck cancers for men and women
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Passive smoking increases sleep disturbance among pregnant women
10. Trial to Test Gene Therapy for Angina in Women
11. Exercise and yoga improves quality of life in women with early-stage breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... 03, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... New York City, with long-time partners The Paul Foundation, on November 10, 2016. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Entrepreneurial Company in the Dallas area” Tuesday evening at the 26th Annual SMU ... presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by ...
(Date:12/4/2016)... , ... December 04, 2016 , ... Responsible dental care ... must brush properly to achieve optimal results. This important necessity inspired an inventor from ... for a way to ensure that people break or avoid bad techniques of brushing ...
(Date:12/2/2016)... SAN DIEGO, Calif. (PRWEB) , ... December 02, 2016 , ... ... Recognition Event at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight ... as myeloproliferative neoplasms (MPNs) by going above and beyond the standard of care, demonstrating ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  PipelineRx, a leading medication management ... offering demonstrations of its SaaS-based telepharmacy platform, ... Pharmacists 2016 Midyear Clinical Meeting and Exhibition, December ... With nearly 300 hospital clients nationally, the Company ... designed to dramatically improve pharmacy operations, enhance patient ...
(Date:12/2/2016)... -- On Thursday, December 1st 2016, the ... development and innovation in the biopharmaceutical industry at its ... the presence of Sergey Tsyb, Vice Minister of Industry ... , Natalia Sanina, First Vice Chairman of the State ... Roszdravnadzor, National Service of Control in Healthcare, Sergey Muravev, ...
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
Breaking Medicine Technology: